{
  "docId": "019de073-4472-76ed-a8f3-3d6ae669b88a",
  "docSlug": "6078678dfcf31020360c86ce90f559c0",
  "documentTitle": "BioNTech | Results Presentation Deck | 32 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 32,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "other",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide highlights the mechanism of action for bispecific antibodies and a monospecific HexaBody, emphasizing their role in T cell and NK cell activation.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de073-4472-76ed-a8f3-3d6ae669b88a/21",
  "deckHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a",
  "deckJsonHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a.json",
  "deckAnchorHref": "/decks/019de073-4472-76ed-a8f3-3d6ae669b88a#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.18,
        "x": 0.745,
        "y": 0.335
      },
      "kind": "image",
      "text": "GEN1053 / BNT313 HexaBody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "08172fb5-3968-40a3-b606-bfe9f3ce5d77",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.18,
        "x": 0.138,
        "y": 0.335
      },
      "kind": "image",
      "text": "GEN1046 / BNT311 antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b2b6b4f-3a0b-4a03-8d1a-2f3dd21e755d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.18,
        "x": 0.45,
        "y": 0.335
      },
      "kind": "image",
      "text": "GEN1042 / BNT312 antibody diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a79eceef-4be7-4809-a43e-56510e91a9f2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.06,
        "y": 0.585
      },
      "kind": "list",
      "text": "Phase 2: R/R NSCLC; Phase 1/2: Advanced solid tumors; Bispecific antibody: Conditional 4-1BB co-stimulation while blocking PD-(L)1 axis",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40dbce5e-db16-4e55-8b1d-be0084aa1b94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.66,
        "y": 0.585
      },
      "kind": "list",
      "text": "Phase 1/2: Solid tumors; FPD expected in 2H 2022; Monospecific HexaBody targeting CD27 on naïve and activated T cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79902a75-5231-4e27-b4e7-e858dc1f4fa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.36,
        "y": 0.585
      },
      "kind": "list",
      "text": "Phase 1/2: Advanced solid tumors; Bispecific antibody: Combines targeting and conditional activation of CD40 and 4-1BB on immune cells",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3037ddd-8d72-4e0b-8993-a1afa6bb44e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.704,
        "x": 0.148,
        "y": 0.825
      },
      "kind": "paragraph",
      "text": "Next-generation immunomodulators designed to prime and activate anti-tumor T cell and Natural Killer cell function",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "efb9ddf6-0c35-44e6-892b-5cee5e987dfa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.048,
        "y": 0.935
      },
      "kind": "source-note",
      "text": "1 Collaboration with Genmab based on 50/50 sharing of costs and profits; 2 HexaBody technology owned by Genmab",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d1a5ff9-738b-40e1-8f42-96ab12f70f1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.425,
        "x": 0.048,
        "y": 0.105
      },
      "kind": "title",
      "text": "Expanding Strategic Collaboration With Genmab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b78e495-812d-4d42-a990-2f69f2685d99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}